Chief Fellow @HemOncMiami @univmiami @SylvesterCancer | Former Chief Resident @MountAuburnHosp @MAHIMRes @HarvardMed | NHLMMC Alum| @COVID19nCCC
Joined May 2013
- Tweets2.2K
- Following1.8K
- Followers1.5K
- Likes3.5K
Chinmay Jani retweeted
1/ November is Lung Cancer Awareness Month.
We cannot make assumptions about our patients' preferences, perspectives and priorities
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
🚀 Just 10 days to go!
Excited to see our fellows, residents, and faculty colleagues to the 2026 @FLASCO_ORG Fellows & Residents Training Program in Orlando!
Grateful to @RManochakian and all our outstanding faculty for their support and participation.
📅 November 21 | Orlando, FL
Looking forward to seeing everyone there! 🙌 @GlopesMd @VamsiVelcheti @DocOncMD @mbilusic @JavierMilian18 @DrPlatelet @EddieSantosMD
📣‼️As a proud member of @FLASCO_ORG #BoardOfDirectors, I invite #HematologyOncology colleagues, #Fellows & #Residents with #HemOnc interest to the:
⭐️ #FLASCO 2026 Fellows & Residents #TrainingProgram.
❇️ #FREE full-day program that bring together #Trainees, #ProgramDirectors and practicing #Oncologists & leaders for practical education sessions on:
✅#Board preparation
✅#Research
✅#Career development & #Mentorship
✅#Transition from training to practice
🗓️Saturday, November 21, 2026
📍JW Marriott Orlando Bonnet Creek Resort & Spa
2
213
🧬 Why are we seeing lung cancer in younger adults who have never smoked? And how can precision medicine change their outcomes?
It was a pleasure joining @CancerNetwork's Oncology On the Go podcast to discuss the evolving landscape of lung cancer in younger adults, emerging risk factors, and the importance of comprehensive molecular profiling.
As we continue to uncover age-related differences in tumor genomics, understanding these unique molecular characteristics is essential to advancing personalized treatment strategies.
🎙️ Grateful to the CancerNetwork team for the opportunity to share our perspectives and research!
🎧 Listen here: hubs.li/Q04D_qjN0
#LungCancer #PrecisionOncology #NSCLC #Genomics #MolecularTesting #ThoracicOncology
@SylvesterCancer @GlopesMd @Latinamd @Jonathanwlee23 @OncWithGrant @YoungLungCancer @HemOncMiami
🎙️ On Oncology On the Go, @Jani_Chinmay discusses lung cancer in younger adults who have never smoked and how molecular testing may guide treatment.
Listen on Apple Podcasts, Spotify, or at:
hubs.li/Q04D_qjN0
#LungCancer #ThoracicOncology #PrecisionOncology
Chinmay Jani retweeted
Five plus years in the making! From an idea at the bench to a clinical trial at the bedside. 🧬
Excited to share the first clinical results from our investigator-initiated Phase 1 trial of the oncolytic Seneca Valley Virus (SVV-001) in combination with nivolumab and ipilimumab for patients with high-grade neuroendocrine neoplasms, presented at NANETS 2026.
This study is particularly close to my heart.
What started as a scientific concept more than 5 years ago evolved through preclinical collaborations with Seneca Therapeutics, study design, countless rounds of protocol development, regulatory discussions with the FDA, and ultimately the launch of this investigator-initiated clinical trial.
Today, we have successfully completed Part A (single-dose escalation)!
🔬 Key findings from Part A:
✅ 13 patients enrolled, representing a diverse spectrum of high-grade NENs, including small-cell NEC, large-cell NEC, and well-differentiated Grade 3 NET.
✅ No dose-limiting toxicities (DLTs) across all three dose levels.
✅ Two partial responses, including an impressive case of complete metabolic response on PET imaging.
✅ Part A evaluated a single intratumoral injection of SVV-001 combined with nivolumab and ipilimumab, with the primary objective of establishing safety and tolerability.
But perhaps the most exciting chapter is just beginning! 🚀
We are now moving into Part B, where we will explore multiple intratumoral doses of SVV-001 in combination with dual immune checkpoint blockade.
The scientific hypothesis is compelling: Can an oncolytic virus turn an immunologically resistant tumor into one that responds to immunotherapy? And could repeated viral administration amplify this effect?
These are early findings from a small Phase 1 study, but they provide an encouraging foundation for the next stage of investigation.
Beyond the science, this journey has reinforced something I deeply believe in: Investigator-initiated research is a team sport .
I am immensely grateful to our collaborators at Seneca Therapeutics, Dr. Peter Hosein (my mentor and colleague), Dr. Paul Hallenbeck, Dr. Isildinha Reis, Rakhi Modak, Dr. Chinmay Jani, and our entire clinical research team.
Along the way, we also forged meaningful partnerships. Stay tuned for Part B at Univ of Miami and UCSF
@PeterHoseinMD @Jani_Chinmay @SylvesterCancer @UCSFCancer
Our prior work in this domain:
Clinical Application of Oncolytic Viruses: A Systematic Review (2020) – Cook & Chauhan. International Journal of Molecular Sciences.
doi.org/10.3390/ijms21207505
SVV and TEM8/ANTXR1 review (2022) – Corbett, Hallenbeck, Rychahou & Chauhan. Frontiers in Molecular Biosciences.
doi.org/10.3389/fmolb.2022.9…
TEM8 in Oncogenesis (2023) – Kareff, Corbett, Hallenbeck & Chauhan. Cells.
doi.org/10.3390/cells1222262…
ANTXR1 as a Prognostic Biomarker (2025) – Franco, Arunachalam, Chauhan, Kareff & Hallenbeck. Frontiers in Molecular Biosciences.
doi.org/10.3389/fmolb.2024.1…
Genomic, Transcriptomic, and Immunologic Landscape of TEM8/ANTXR1 in Neuroendocrine Neoplasms, Including SCLC (2026) – Kareff et al., including Chauhan. Cancer Treatment and Research Communications.
doi.org/10.1016/j.ctarc.2026…
Key preclinical evidence:
SVV-001 Overcomes Checkpoint Inhibitor Resistance and Demonstrates Systemic Antitumor Immunity (AACR 2022) – Hallenbeck & Chada. Cancer Research, Abstract 6218.
doi.org/10.1158/1538-7445.AM…
Key discovery:
ANTXR1 Is the Cellular Receptor for Seneca Valley Virus (2017) – Miles et al. Journal of Clinical Investigation.
doi.org/10.1172/JCI93472
🤖 Grateful to @SylvesterCancer for the recognition at the Sylvester Innovator 2026 Showcase!
Our projects explored:
🔬 AI platforms for clinical decision-making in oncology - focused on EGFR Lung cancers.
📊 AI-assisted meta-analysis & network meta-analysis in collaboration with @Larvol to identify best trial match for specific subgroup population in Lung Cancer.
AI is evolving rapidly, and its thoughtful integration into healthcare holds tremendous potential to advance precision medicine and evidence-based cancer care.
Thankful to our mentors for constant support! @GlopesMd @dan_morgen @Latinamd @DionysiosWatson @DrSDNimer @EGFRResisters @jillfeldman4
Chinmay Jani retweeted
Thrilled to present at the @NYCHealthSystem Lung Cancer Awareness Symposium today. Great to learn about the phenomenal care NYHH are providing to vulnerable New Yorkers.
Chinmay Jani retweeted
Our ONWARD-SCLC @JTOonline: real-world tarlatamab (n=265)
➡️ DCR 52.6% (evaluable); mPFS 2.3, mOS 8.0 mo
➡️ C1 CRS 40.8%, ICANS 21.5%; G≥3 above trials
➡️ Toci ppx (n=19): CRS 5.3 vs 43.0%
Ppx toci trial next?
doi.org/10.1016/j.jtho.2026.…
@LungCancerRx @OncoAlert @oncodaily
Looks like my next birthday celebration will involve sunshine, oncology, and some friendly disagreements - with references. 🎂📚🌴
Looking forward to @OLNGreatDebates in Miami, March 13–14, 2027! What better way to celebrate than learning from colleagues and enjoying Miami in March?
Come for the science, stay for the sunshine, and help me make the case that this counts as a birthday party. 😄
Save the date. I’ll work on the cake. 🎂
#GreatDebates #Oncology #MedEd #Miami
@GlopesMd @lungoncdo @Niraj_Kapur @SylvesterCancer
🚨 Don’t forget to submit your abstract for the @OncLive National Fellows Forum: Lung Cancer!
Excited to join an incredible group of thoracic oncology leaders in Scottsdale on December 3!
Looking forward to hearing innovative research from the next generation of oncologists! 🫁🔬
#LungCancer #OncologyFellows #ThoracicOncology
@NarjustFlorezMD @christinemphmd @AnaVManana
Last call: abstracts for OncLive® National Fellows Forum: Lung Cancer, chaired by Narjust Florez, MD, FASCO; Christine A. Garcia, MD, MPH; Ana Velázquez Mañana, MD, MSc, FASCO, and guest speaker Chinmay Jani, MD, close Fri, Oct 30 at 11:59 PM ET. 15 fellows will present in Scottsdale on Dec 3, the day before NACLC.
Submit your abstract: [ABSTRACT SURVEY LINK]
@NarjustFlorezMD @DanaFarber @christinemphmd @WeillCornell @AnaVManana @panoncology @Jani_Chinmay @SylvesterCancer #lcsm #NACLC26 #FellowsForum
Chinmay Jani retweeted
Happy Diwali and very successful
lung cancer biomarker testing everyone!
#lcsm
🚀 The countdown is on! Just 2 weeks until the 2026 @FLASCO_ORG Fellows & Residents Training Program!
Excited to help lead an incredible day dedicated to the next generation of oncology leaders!
📚 High-yield board review
🔬 Research & mentorship
🎯 Career development
🤝 Networking with oncology leaders
🏆 NEW this year: Oncology Jeopardy Cup! Starting a new tradition of friendly competition between fellowship programs, with the championship cup changing hands each year!
📅 November 21 | Orlando, FL
🔗 flasco.org/events/
#Oncology #Hematology #MedEd #mentorship
@DocOncMD @EddieSantosMD @SylvesterCancer @HemOncMiami @GlopesMd @RManochakian – at Doral, FL
🧬 Can T-cell engagers redefine the future of solid tumor oncology?
Excited to share our new review: “T-cell engagers in solid tumors: challenges and emerging strategies"
The success of tarlatamab in #SCLC and tebentafusp in uveal melanoma has opened exciting possibilities for T-cell–redirecting therapies beyond hematologic malignancies.
🔬 In our review, we explore:
🔹 The evolving landscape of T-cell engagers in solid tumors
🔹 Challenges of antigen heterogeneity, immunosuppressive tumor microenvironment & treatment resistance
🔹 Advances in bispecific and multispecific antibody engineering
🔹 Emerging strategies to improve efficacy, tumor selectivity & safety
📖 Read at: doi.org/10.3389/fimmu.2026.1…
#CancerImmunotherapy #TCellEngagers #BispecificAntibodies #SolidTumors #ImmunoOncology
@mbilusic @RuchiJani27 @XenaZhengMD @HemOncMiami @SylvesterCancer – at Doral, FL
Chinmay Jani retweeted
So proud of our fellow @dan_morgen presenting his work on age, sex and ancestry-associated differences in EGFR alterations in a real-world NSCLC cohort at #EGFRSummit!🧬
Great collaboration work👏@SylvesterCancer, @Labcorp @DanaFarber @GlopesMd @Jani_Chinmay @Latinamd @COlazagasti @RuchiJani27
Dan Morgenstern-Kaplan, MD, MSc @dan_morgen of @SylvesterCancer presents “Age, Sex, and Ancestry-Associated Differences in EGFR Alteration Prevalence, Actionability, and Variant Composition in a Real-World NSCLC Cohort.”
#EGFR #MedEd #MedTwitter #MedX #EGFRSummit
Chinmay Jani retweeted
Sharing our real-world experience with #tarlatamab from the #ONWARD consortium. Important real-world insights into the effectiveness and safety of tarlatamab in patients with SCLC via @JTOonline . #LCSM
▶️ Median real-world PFS 2.3 mos and OS: 8.0 mos
▶️ Following Cycle 1 Day 1, CRS occurred in 40.8% (Grade 3–4: 3.8%) and ICANS in 21.5% (Grade 3–4: 6%), with incidence declining substantially with subsequent doses.
Work led by @Sonampuri @JhanelleGray @AmanChauhanMD @Jani_Chinmay et al.
Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from the ONWARD consortium - Journal of Thoracic Oncology jto.org/article/S1556-0864%2…
Chinmay Jani retweeted
1/7 🫁 A T-shirt, six C's, a Nobel Prize, and why investing in science matters. During my September visit to Asia for WCLC and UICC meetings, I picked up this UNIQLO shirt designed with Professor Tasuku Honjo.
Leadership is not just about accomplishments - it is about the impact we create and the people we empower along the way!
Having had the privilege of collaborating with @montypal across kidney cancer research and global oncology initiatives, I have witnessed his exceptional commitment to advancing cancer research, mentorship, and supporting the next generation of oncologists.
His vision, experience, and dedication would be tremendous assets to the @ASCO Board!
I strongly encourage all eligible ASCO members to cast their vote for @montypal !
🗳️ asco.org/election
@ASCOTECAG @OncUpdates @oncodaily @OncBrothers @GlopesMd @Latinamd @neerajaiims @JamesFanWu @HemOncFellows @OncoAlert @sawyer_bawek @DrSAHaddad @CancerNetwrk @OncWithGrant @Jonathanwlee23 @FLASCO_ORG @EddieSantosMD @LuisRaezMD @DocOncMD
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Chinmay Jani retweeted
So proud to see @samanthawarrak leading the conversation at the @FLASCO_ORG Women's Cancer Care series! 👏 Biomarker-driven sequencing in metastatic breast cancer is where real progress for patients is happening💗 #BreastCancer
Great panel discussion at the @FLASCO_ORG Clinical Oncology Series: Women’s Cancer Care! We explored two key topics in breast oncology: biomarker-driven treatment sequencing in metastatic disease and treatment de-escalation in early-stage disease💓 @HemOncMiami @SylvesterCancer @Latinamd #breastcancer
Chinmay Jani retweeted
ASCO Election
The ASCO Nominating Committee has selected 11 distinguished members as candidates for open leadership positions within the Society.
ASCO encourages all eligible members to cast their ballots to choose new Society leaders. Eligible members are those who have been awarded and hold the degree of Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Medical Science, Doctor of Nursing Science, Doctor of Nursing Practice, or equivalent doctoral-level degree as determined by the Society and the Association, and who are in good standing as of October 13, 2026. Eligible members will earn a FASCO point for voting in the ASCO Election.
The voting period closes on Wednesday, December 2, 2026, at 3:00 PM Eastern Standard Time, USA. All ballots (online or paper) must be received by this time.
@iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @latinamd @colazagasti @openmedicineHQ @asco @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @lungoncdoc @OncodailyLung @ClinicalLung #LCSM
Chinmay Jani retweeted
Grateful to the @TheVFoundation, the @MiamiDolphins @TackleCancer and @ElicioTx for their tremendous support in this important work @SylvesterCancer. Also massively indebted to my Co-PI @DrJashDatta for his foresight and insights in bringing this project together!
An experimental pancreatic cancer vaccine triggered an immune response in 89 of 90 evaluable patients. 🙌
Now, a $1M V Foundation grant will help Sylvester researchers led by @PeterHoseinMD investigate why some cancers return despite vaccination. Learn more: spr.ly/6015BH9Pi7
Chinmay Jani retweeted
A pleasure to catch up with so many terrific people at #ESMO26! @tompowles1, @DrChoueiri, @FedefedeFri, @alshamsi2000, @DrYukselUrun, @ProfSyedHussain, @ErikaHamilton9, @jrgralow, @MatteoSantoniMD, @chadinabhan, @OncHahn, @TiansterZhang, @AnaVManana - and that's just skimming the surface! #Oncology truly takes a village & this meeting has brought so many drivers of progress under one roof!
